A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Tominersen (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms GENERATION HD2
- Sponsors Roche; Roche Farma
Most Recent Events
- 28 May 2025 Planned primary completion date changed from 28 Feb 2026 to 31 May 2026.
- 20 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2024 Planned End Date changed from 4 Jan 2027 to 1 Apr 2027.